Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US90400D1081
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG001RWPDW6
RARE

Ultragenyx Pharmaceutical Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Ultragenyx Pharmaceutical Inc
ISIN
US90400D1081
TICKER
RARE
MIC
XNAS
REUTERS
RARE.OQ
BLOOMBERG
RARE US
Fri, 27.02.2026       Ultragenyx Pharmaceutical

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Ultragenyx Pharmaceutical
Fri, 27.02.2026       Ultragenyx Pharmaceutical

SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, both dates inclusive (the "Class Period"), have until Monday, April 6, 2026 to seek appointment as lead plaintiff...
Ultragenyx Pharmaceutical
Fri, 27.02.2026       Ultragenyx Pharmaceutical

NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusiv...
Ultragenyx Pharmaceutical
Thu, 26.02.2026       Ultragenyx Pharmaceutical

NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire b...
Ultragenyx Pharmaceutical
Thu, 26.02.2026       Ultragenyx Pharmaceutical

San Diego, California--(Newsfile Corp. - February 25, 2026) - The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), have until Monday, April 6, 2026 to seek appointment as lead...
Ultragenyx Pharmaceutical
Wed, 25.02.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - February 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If...
Ultragenyx Pharmaceutical
Wed, 25.02.2026       Ultragenyx Pharmaceutical

Time-Sensitive: Allegations Focus on Repeated Assurances Regarding Setrusumab EfficacyRARE INVESTOR ALERT"Investors deserve transparency about material risks that could affect their investments," stated Joseph E. Levi, Esq., managing partner of Levi & Korsinsky, LLP. "The adequacy of clinical trial risk disclosures is a fundamental issue for b...
Ultragenyx Pharmaceutical
Wed, 25.02.2026       Ultragenyx Pharmaceutical

Did you buy RARE common stock between August 3, 2023, and December 26, 2025?Affected Ultragenyx Pharmaceutical Inc. Investor SummaryWho: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)What: Securities fraud class action lawsuit filedClass Period: August 3, 2023, through December 26, 2025Deadline to Seek Lead Plaintiff Status: April 6, 2026Key Lawsui...
Ultragenyx Pharmaceutical
Tue, 24.02.2026       Ultragenyx Pharmaceutical

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Ultragenyx Pharmaceutical
Tue, 24.02.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - February 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If...
Ultragenyx Pharmaceutical
Silent Ad
Tue, 24.02.2026       Ultragenyx Pharmaceutical

Philadelphia, Pennsylvania--(Newsfile Corp. - February 24, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased Ultragenyx common stock during the period from August 3, 2...
Ultragenyx Pharmaceutical
Tue, 24.02.2026       Ultragenyx Pharmaceutical

NEW YORK, Feb. 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are enco...
Ultragenyx Pharmaceutical
Mon, 23.02.2026       Ultragenyx Pharmaceutical

NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in three upcoming investor conferences....
Ultragenyx Pharmaceutical
Mon, 23.02.2026       Ultragenyx Pharmaceutical

PDUFA action date set for August 23, 2026...
Ultragenyx Pharmaceutical
Mon, 23.02.2026       Ultragenyx Pharmaceutical

LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commissio...
Ultragenyx Pharmaceutical
Mon, 23.02.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - February 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you p...
Ultragenyx Pharmaceutical
Sat, 21.02.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - February 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If...
Ultragenyx Pharmaceutical
Sat, 21.02.2026       Ultragenyx Pharmaceutical

NEW ORLEANS, Feb. 20, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE), if they purchased or otherwise acquire...
Ultragenyx Pharmaceutical
Fri, 20.02.2026       Ultragenyx Pharmaceutical

NOVATO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 22,917 restricted stock units of the company’s common stock to six newly hired non-executive...
Ultragenyx Pharmaceutical
Fri, 20.02.2026       Ultragenyx Pharmaceutical

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Far...
Ultragenyx Pharmaceutical
Silent Ad
Fri, 20.02.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - February 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you p...
Ultragenyx Pharmaceutical
Fri, 20.02.2026       Ultragenyx Pharmaceutical

NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire b...
Ultragenyx Pharmaceutical
Thu, 19.02.2026       Ultragenyx Pharmaceutical

SAN DIEGO, Feb. 19, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, all dates inclusive (the "Class Period"), have until April 6, 2026 to seek appointment as lead plaintiff of the Ultragenyx class...
Ultragenyx Pharmaceutical
Thu, 19.02.2026       Ultragenyx Pharmaceutical

NEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are enco...
Ultragenyx Pharmaceutical
Thu, 19.02.2026       Ultragenyx Pharmaceutical

Did you buy RARE common stock between August 3, 2023, and December 26, 2025?Affected Ultragenyx Pharmaceutical Inc. Investor SummaryWho: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)What: Securities fraud class action lawsuit filedClass Period: August 3, 2023, through December 26, 2025Deadline to seek lead plaintiff status: April 6, 2026Key Lawsui...
Ultragenyx Pharmaceutical
Wed, 18.02.2026       Ultragenyx Pharmaceutical

Philadelphia, Pennsylvania--(Newsfile Corp. - February 18, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased Ultragenyx common stock during the period from August 3, 2...
Ultragenyx Pharmaceutical
Wed, 18.02.2026       Ultragenyx Pharmaceutical

NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit...
Ultragenyx Pharmaceutical
Tue, 17.02.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - February 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.SO WHAT: If y...
Ultragenyx Pharmaceutical
Tue, 17.02.2026       Ultragenyx Pharmaceutical

NEW YORK, Feb. 16, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusiv...
Ultragenyx Pharmaceutical
Mon, 16.02.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - February 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you p...
Ultragenyx Pharmaceutical
Mon, 16.02.2026       Ultragenyx Pharmaceutical

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Ultragenyx Pharmaceutical
Sun, 15.02.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - February 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"). A class action lawsuit has alr...
Ultragenyx Pharmaceutical
Sat, 14.02.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - February 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"). A class action lawsuit has alr...
Ultragenyx Pharmaceutical
Sat, 14.02.2026       Ultragenyx Pharmaceutical

NEW YORK and NEW ORLEANS, Feb. 13, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE) of a class action securities lawsuit.   CLASS DEFINIT...
Ultragenyx Pharmaceutical
Sat, 14.02.2026       Ultragenyx Pharmaceutical

The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”), have until April 6, 2026 to seek appointment as lead plaintiff of the Ultragenyx class action lawsuit. Captioned Bailey v....
Ultragenyx Pharmaceutical
Fri, 13.02.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - February 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025. A class action lawsuit has already been filed. If you wish to serve...
Ultragenyx Pharmaceutical
Thu, 12.02.2026       Ultragenyx Pharmaceutical

2025 total revenue of $673 million,Crysvita® revenue of $481 million and Dojolvi® revenue of $96 million...
Ultragenyx Pharmaceutical
Thu, 12.02.2026       Ultragenyx Pharmaceutical

Did you buy RARE common stock between August 3, 2023, and December 26, 2025?Affected Ultragenyx Pharmaceutical Inc. Investor SummaryWho: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)What: Securities fraud class action lawsuit filedClass Period: August 3, 2023, through December 26, 2025Deadline to seek lead plaintiff status: April 6, 2026Key Lawsui...
Ultragenyx Pharmaceutical
Thu, 12.02.2026       Ultragenyx Pharmaceutical

NEW YORK, Feb. 11, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3...
Ultragenyx Pharmaceutical
Wed, 11.02.2026       Ultragenyx Pharmaceutical

Philadelphia, Pennsylvania--(Newsfile Corp. - February 11, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased common shares of Ultragenyx during the period from August...
Ultragenyx Pharmaceutical
Wed, 11.02.2026       Ultragenyx Pharmaceutical

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Ultragenyx Pharmaceutical
Wed, 11.02.2026       Ultragenyx Pharmaceutical

NEW YORK, Feb. 11, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit...
Ultragenyx Pharmaceutical
Tue, 10.02.2026       Ultragenyx Pharmaceutical

Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (Ultragenyx) (NASDAQ: RARE) on behalf of those who purchased or acquired Ultragenyx common stock between August 3, 2023, and December 26, 2025, inclusive. The lawsuit is filed in...
Ultragenyx Pharmaceutical
Tue, 10.02.2026       Ultragenyx Pharmaceutical

Philadelphia, Pennsylvania--(Newsfile Corp. - February 10, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased Ultragenyx common stock during the period from August 3, 2...
Ultragenyx Pharmaceutical
Tue, 10.02.2026       Ultragenyx Pharmaceutical

SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, both dates inclusive (the "Class Period"), have until April 6, 2025 to seek appointment as lead plaintiff of the Ultragenyx class...
Ultragenyx Pharmaceutical
Mon, 09.02.2026       Ultragenyx Pharmaceutical

New York, New York--(Newsfile Corp. - February 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025. A class action lawsuit has already been filed. If you wish to s...
Ultragenyx Pharmaceutical
Mon, 09.02.2026       Ultragenyx Pharmaceutical

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Ultragenyx Pharmaceutical
Sun, 08.02.2026       Ultragenyx Pharmaceutical

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Ultragenyx Investors Who Suffered Losses Exceeding $50,000 To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi &...
Ultragenyx Pharmaceutical
Sat, 07.02.2026       Ultragenyx Pharmaceutical

NEW ORLEANS, Feb. 6, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE), if they purchased or otherwise acquired...
Ultragenyx Pharmaceutical
Fri, 06.02.2026       Ultragenyx Pharmaceutical

The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, both dates inclusive (the “Class Period”), have until April 6, 2025 to seek appointment as lead plaintiff of the Ultragenyx class action lawsuit. Captione...
Ultragenyx Pharmaceutical